

# Scott H Kaufmann

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4741628/scott-h-kaufmann-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

314  
papers

23,782  
citations

78  
h-index

148  
g-index

434  
ext. papers

25,967  
ext. citations

6.6  
avg, IF

6.71  
L-index

#	Paper	IF	Citations
314	Therapeutics targeting BCL2 family proteins <b>2022</b> , 197-260		0
313	Uncovering Pharmacological Opportunities for Cancer Stem Cells-A Systems Biology View.. <i>Frontiers in Cell and Developmental Biology</i> , <b>2022</b> , 10, 752326	5.7	1
312	A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2022</b> , 89, 721	3.5	0
311	Machine-learning aided in situ drug sensitivity screening predicts treatment outcomes in ovarian PDX tumors.. <i>Translational Oncology</i> , <b>2022</b> , 21, 101427	4.9	
310	A Phase I Study of Pevonedistat, Azacitidine and Venetoclax for Patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML). <i>Blood</i> , <b>2021</b> , 138, 2347-2347	2.2	
309	Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , <b>2021</b> , 4, 125-142	4.5	10
308	Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells. <i>Cell Death and Disease</i> , <b>2021</b> , 12, 977	9.8	2
307	Targeting LRRC15 inhibits metastatic dissemination of ovarian cancer. <i>Cancer Research</i> , <b>2021</b> ,	10.1	2
306	Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. <i>JAMA Oncology</i> , <b>2021</b> ,	13.4	6
305	TFEB links MYC signaling to epigenetic control of myeloid differentiation and acute myeloid leukemia. <i>Blood Cancer Discovery</i> , <b>2021</b> , 2, 162-185	7	6
304	USP13 regulates the replication stress response by deubiquitinating TopBP1. <i>DNA Repair</i> , <b>2021</b> , 100, 103063	4.3	2
303	Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting. <i>Scientific Reports</i> , <b>2021</b> , 11, 8076	4.9	2
302	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). <i>Nature Communications</i> , <b>2021</b> , 12, 2487	17.4	24
301	RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. <i>Nature Communications</i> , <b>2021</b> , 12, 2901	17.4	12
300	The Trifecta of Single-Cell, Systems-Biology, and Machine-Learning Approaches. <i>Genes</i> , <b>2021</b> , 12,	4.2	1
299	Invasion of Endometrial Cancer Cells. <i>Frontiers in Microbiology</i> , <b>2021</b> , 12, 674835	5.7	0
298	Characterization of a -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. <i>NAR Cancer</i> , <b>2021</b> , 3, zcab028	5.2	4

297	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. <i>Modern Pathology</i> , <b>2021</b> , 34, 194-206	9.8	6
296	Circulating CD14 HLA-DR monocytic cells as a biomarker for epithelial ovarian cancer progression. <i>American Journal of Reproductive Immunology</i> , <b>2021</b> , 85, e13343	3.8	1
295	CDK2-Mediated Upregulation of TNF $\alpha$ s a Mechanism of Selective Cytotoxicity in Acute Leukemia. <i>Cancer Research</i> , <b>2021</b> , 81, 2666-2678	10.1	1
294	The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia - A Single Center Retrospective Study. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , <b>2021</b> , 11, 1-9	2.6	2
293	Acquired Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma. <i>Cancer Research</i> , <b>2021</b> , 81, 4709-4722	10.1	11
292	Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer. <i>Cell Death and Disease</i> , <b>2021</b> , 12, 789	9.8	0
291	Manifold medicine: A schema that expands treatment dimensionality. <i>Drug Discovery Today</i> , <b>2021</b> , 27, 8-8	8.8	0
290	Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , <b>2021</b> , 163, 490-497	4.9	3
289	Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.. <i>Cell Reports Medicine</i> , <b>2021</b> , 2, 100471	18	2
288	PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword.. <i>Cancers</i> , <b>2021</b> , 13,	6.6	6
287	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5411-5423	12.9	21
286	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 793-802	8.7	16
285	FAM111A protects replication forks from protein obstacles via its trypsin-like domain. <i>Nature Communications</i> , <b>2020</b> , 11, 1318	17.4	25
284	Rare Missense Alleles Confer Risk for Ovarian and Breast Cancer. <i>Cancer Research</i> , <b>2020</b> , 80, 857-867	10.1	13
283	Characterization of an alternative BAK-binding site for BH3 peptides. <i>Nature Communications</i> , <b>2020</b> , 11, 3301	17.4	9
282	The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 3397-3407	12.9	23
281	Tfeb Links MYC Signaling to Epigenetic Control of Acute Myeloid Leukemia Cell Death and Differentiation. <i>Blood</i> , <b>2020</b> , 136, 12-13	2.2	
280	Therapeutic options for mucinous ovarian carcinoma. <i>Gynecologic Oncology</i> , <b>2020</b> , 156, 552-560	4.9	21

279	Reactivating latent HIV with PKC agonists induces resistance to apoptosis and is associated with phosphorylation and activation of BCL2. <i>PLoS Pathogens</i> , <b>2020</b> , 16, e1008906	7.6	8
278	Selective Inhibition of BFL1: It's All about Finding the Right Partner. <i>Cell Chemical Biology</i> , <b>2020</b> , 27, 639-642	8.4	8
277	Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor $\beta$ . <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 2986-2996	12.9	8
276	The molecular origin and taxonomy of mucinous ovarian carcinoma. <i>Nature Communications</i> , <b>2019</b> , 10, 3935	17.4	59
275	53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. <i>Gynecologic Oncology</i> , <b>2019</b> , 153, 127-134	4.9	35
274	Genes associated with bowel metastases in ovarian cancer. <i>Gynecologic Oncology</i> , <b>2019</b> , 154, 495-504	4.9	21
273	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. <i>Cancer Medicine</i> , <b>2019</b> , 8, 2503-2513	4.8	4
272	Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo. <i>Scientific Reports</i> , <b>2019</b> , 9, 3617	4.9	4
271	Olaparib and $\beta$ -specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 570-580	21.7	118
270	BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents. <i>Cancer Research</i> , <b>2019</b> , 79, 5920-5929	10.1	23
269	ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancer. <i>Nature Communications</i> , <b>2019</b> , 10, 4632	17.4	9
268	A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML). <i>Blood</i> , <b>2019</b> , 134, 3837-3837	2.2	3
267	Topoisomerases and cancer chemotherapy: recent advances and unanswered questions. <i>F1000Research</i> , <b>2019</b> , 8,	3.6	27
266	Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures. <i>Blood</i> , <b>2019</b> , 134, 1710-1710	2.2	
265	A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors. <i>Investigational New Drugs</i> , <b>2019</b> , 37, 307-314	4.3	4
264	Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , <b>2019</b> , 9, 210-219	24.4	142
263	A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 111-117.1	7.1	19
262	Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression. <i>Biochemical Pharmacology</i> , <b>2018</b> , 152, 279-292	6	23

261	Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 1228-1238	13.4	8
260	Measurement of BH3-only protein tolerance. <i>Cell Death and Differentiation</i> , <b>2018</b> , 25, 282-293	12.7	10
259	Gadolinium-enhanced cardiac MR exams of human subjects are associated with significant increases in the DNA repair marker 53BP1, but not the damage marker H2AX. <i>PLoS ONE</i> , <b>2018</b> , 13, e0190890	3.7	1
258	A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 744-752	12.9	29
257	Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. <i>Nature Communications</i> , <b>2018</b> , 9, 3970	17.4	111
256	Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. <i>Cell Metabolism</i> , <b>2018</b> , 28, 833-847.e8	24.6	25
255	Spartan deficiency causes accumulation of Topoisomerase 1 cleavage complexes and tumorigenesis. <i>Nucleic Acids Research</i> , <b>2017</b> , 45, 4564-4576	20.1	63
254	Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , <b>2017</b> , 18, 75-87	21.7	706
253	Secondary Somatic Mutations Restoring and Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , <b>2017</b> , 7, 984-998	24.4	193
252	Maintenance of the HIV Reservoir Is Antagonized by Selective BCL2 Inhibition. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	42
251	Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 4077-4085	12.9	54
250	Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia. <i>Leukemia Research</i> , <b>2017</b> , 61, 108-116	2.7	25
249	Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine. <i>Oncotarget</i> , <b>2017</b> , 8, 94569-94579	3.3	2
248	Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo. <i>Stem Cells Translational Medicine</i> , <b>2017</b> , 6, 840-850	6.9	5
247	A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 697-706	12.9	40
246	A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 899-907	12.9	26
245	4EBP1/c-MYC/PUMA and NF- $\kappa$ B/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells. <i>Blood</i> , <b>2016</b> , 127, 2711-22	2.2	42
244	In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. <i>Gynecologic Oncology</i> , <b>2016</b> , 143, 379-388	4.9	51

243	Immunodetection of human topoisomerase I-DNA covalent complexes. <i>Nucleic Acids Research</i> , <b>2016</b> , 44, 2816-26	20.1	30
242	APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 4746-55	12.9	37
241	Prime, Shock, and Kill: Priming CD4 T Cells from HIV Patients with a BCL-2 Antagonist before HIV Reactivation Reduces HIV Reservoir Size. <i>Journal of Virology</i> , <b>2016</b> , 90, 4032-4048	6.6	60
240	Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma. <i>JAMA Oncology</i> , <b>2016</b> , 2, 370-2	13.4	68
239	A cell cycle-dependent BRCA1-UHRF1 cascade regulates DNA double-strand break repair pathway choice. <i>Nature Communications</i> , <b>2016</b> , 7, 10201	17.4	75
238	Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5540-5540	2.2	16
237	Mitochondrial apoptosis and BH3 mimetics. <i>F1000Research</i> , <b>2016</b> , 5, 2804	3.6	24
236	Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 3894-902	12.9	15
235	Synthesis of a peptide-universal nucleotide antigen: towards next-generation antibodies to detect topoisomerase I-DNA covalent complexes. <i>Organic and Biomolecular Chemistry</i> , <b>2016</b> , 14, 4103-9	3.9	3
234	Efficient method to optimize antibodies using avian leukosis virus display and eukaryotic cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 9860-5	11.5	3
233	TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer. <i>Nucleic Acids Research</i> , <b>2015</b> , 43, 6945-58	20.1	37
232	Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2015</b> , 1853, 1658-71	4.9	103
231	Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1397-406	2.2	254
230	Histone Deacetylase Inhibitors Target the Leukemic Microenvironment by Enhancing a Nherf1-Protein Phosphatase 1 $\beta$ AZ Signaling Pathway in Osteoblasts. <i>Journal of Biological Chemistry</i> , <b>2015</b> , 290, 29478-92	5.4	14
229	Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells. <i>Genes and Development</i> , <b>2015</b> , 29, 2140-52	12.6	34
228	BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. <i>Blood</i> , <b>2015</b> , 125, 658-67	2.2	79
227	COMMD1 is linked to the WASH complex and regulates endosomal trafficking of the copper transporter ATP7A. <i>Molecular Biology of the Cell</i> , <b>2015</b> , 26, 91-103	3.5	130
226	Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia. <i>Blood</i> , <b>2015</b> , 126, 2563-2563	2.2	2

225	mTOR Dual Inhibitor Induced Cytotoxicity Depends on 4EBP1/c-Myc/Puma and NFkB/Egr-1/Bim Pathways in Human Lymphoid Malignancies. <i>Blood</i> , <b>2015</b> , 126, 3705-3705	2.2	
224	MTH1 Inhibitor-Induced Cytotoxicity in Acute Myeloid Leukemia. <i>Blood</i> , <b>2015</b> , 126, 1273-1273	2.2	
223	Osteoblasts protect AML cells from SDF-1-induced apoptosis. <i>Journal of Cellular Biochemistry</i> , <b>2014</b> , 115, 1128-37	4.7	22
222	Auxin-induced rapid degradation of inhibitor of caspase-activated DNase (ICAD) induces apoptotic DNA fragmentation, caspase activation, and cell death: a cell suicide module. <i>Journal of Biological Chemistry</i> , <b>2014</b> , 289, 31617-23	5.4	23
221	Casp8p41 generated by HIV protease kills CD4 T cells through direct Bak activation. <i>Journal of Cell Biology</i> , <b>2014</b> , 206, 867-76	7.3	23
220	Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression. <i>Journal of Biological Chemistry</i> , <b>2014</b> , 289, 20543-58	5.4	37
219	Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. <i>Molecular Oncology</i> , <b>2014</b> , 8, 656-68	7.9	97
218	Platelet-derived growth factor primes cancer-associated fibroblasts for apoptosis. <i>Journal of Biological Chemistry</i> , <b>2014</b> , 289, 22835-22849	5.4	39
217	Evaluation of the BH3-only protein Puma as a direct Bak activator. <i>Journal of Biological Chemistry</i> , <b>2014</b> , 289, 89-99	5.4	52
216	Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells. <i>Haematologica</i> , <b>2014</b> , 99, 60-9	6.6	21
215	Loss of HSulf-1 expression enhances tumorigenicity by inhibiting Bim expression in ovarian cancer. <i>International Journal of Cancer</i> , <b>2014</b> , 135, 1783-9	7.5	12
214	Context-dependent antagonism between Akt inhibitors and topoisomerase poisons. <i>Molecular Pharmacology</i> , <b>2014</b> , 85, 723-34	4.3	6
213	Tumorgrafts as in vivo surrogates for women with ovarian cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 1288-97	12.9	143
212	ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS5619-TPS5619	2.2	8
211	Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies. <i>Investigational New Drugs</i> , <b>2013</b> , 31, 1201-6	4.3	17
210	Comparison of complication rates of Hickman(□) catheters versus peripherally inserted central catheters in patients with acute myeloid leukemia undergoing induction chemotherapy. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 1263-7	1.9	25
209	CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak. <i>Journal of Biological Chemistry</i> , <b>2013</b> , 288, 22899-914	5.4	45
208	APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. <i>Cancer Research</i> , <b>2013</b> , 73, 7222-31	10.1	123

207	ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. <i>Cancer Research</i> , <b>2013</b> , 73, 3683-91	10.1	137
206	The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells. <i>Frontiers in Oncology</i> , <b>2013</b> , 3, 228	5.3	81
205	Contribution of Bcl-2 phosphorylation to Bak binding and drug resistance. <i>Cancer Research</i> , <b>2013</b> , 73, 6998-7008	10.1	70
204	Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies. <i>Blood</i> , <b>2013</b> , 122, 5000-5000	2.2	
203	Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy. <i>European Journal of Haematology</i> , <b>2012</b> , 88, 237-43	3.8	22
202	A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma. <i>Gynecologic Oncology</i> , <b>2012</b> , 124, 210-5	4.9	19
201	Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. <i>Blood</i> , <b>2012</b> , 119, 476-87	2.2	81
200	Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. <i>Blood</i> , <b>2012</b> , 119, 55-63	2.2	22
199	Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes. <i>Journal of Biological Chemistry</i> , <b>2012</b> , 287, 4198-210	5.4	74
198	How does doxorubicin work?. <i>ELife</i> , <b>2012</b> , 1, e00387	8.9	51
197	Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 6723-31	12.9	87
196	Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 5364-73	12.9	47
195	Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors. <i>Genes and Development</i> , <b>2012</b> , 26, 305-11	12.6	65
194	Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 1655-62	12.9	182
193	Bak Conformational Changes Induced by Ligand Binding: Insight into BH3 Domain Binding and Bak Homo-Oligomerization. <i>Scientific Reports</i> , <b>2012</b> , 2, 257	4.9	36
192	Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio. <i>Blood</i> , <b>2012</b> , 120, 1508-1508	2.2	
191	High cell surface death receptor expression determines type I versus type II signaling. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 35823-35833	5.4	25
190	Death receptor 5 signaling promotes hepatocyte lipoapoptosis. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 39336-48	5.4	93



189	Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. <i>Haematologica</i> , <b>2011</b> , 96, 1619-26	6.6	35
188	Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation. <i>Blood</i> , <b>2011</b> , 118, 4872-81	2.2	26
187	Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. <i>Blood</i> , <b>2011</b> , 118, 4882-9	2.2	32
186	Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 67, 455-63	3.5	15
185	A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer. <i>Cancer Investigation</i> , <b>2011</b> , 29, 617-25	2.1	7
184	Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells. <i>Cancer Research</i> , <b>2011</b> , 71, 4944-54	10.1	37
183	Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization. <i>Journal of Cell Biology</i> , <b>2011</b> , 194, 39-48	7.3	116
182	Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 3406-11	11.5	390
181	Isolation of a TRAIL antagonist from the serum of HIV-infected patients. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 35742-35754	5.4	15
180	Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 17682-92	5.4	72
179	Phase I Dose-Escalation Study of SCH 900776 in Combination with Cytarabine (Ara-C) in Patients with Acute Leukemia. <i>Blood</i> , <b>2011</b> , 118, 1531-1531	2.2	1
178	Phase I Trial of the Oral Poly (ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888, V) Combined With Topotecan (T) and Carboplatin (C) for Adults with Relapsed and Refractory Acute Leukemias,. <i>Blood</i> , <b>2011</b> , 118, 3634-3634	2.2	3
177	Genetic and Epigenetic Defects in DNA Repair Lead to Synthetic Lethality of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors in Aggressive Myeloproliferative Disorders. <i>Blood</i> , <b>2011</b> , 118, 400-400	2.2	4
176	PARP inhibition: PARP1 and beyond. <i>Nature Reviews Cancer</i> , <b>2010</b> , 10, 293-301	31.3	985
175	Prospects for the Use of ATR Inhibitors to Treat Cancer. <i>Pharmaceuticals</i> , <b>2010</b> , 3, 1311-1334	5.2	44
174	Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy. <i>Journal of Biological Chemistry</i> , <b>2010</b> , 285, 888-902	5.4	14
173	Noxa mediates hepatic stellate cell apoptosis by proteasome inhibition. <i>Hepatology Research</i> , <b>2010</b> , 40, 701-10	5.1	5
172	A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas. <i>Blood</i> , <b>2010</b> , 116, 287-287	2.2	0

171	Dual Inhibition of mTORC1/mTORC2 Induces Apoptosis of Mantle Cell Lymphoma by Preventing Rictor Mediated AKTS473 Phosphorylation by Potentiating AKT2-PHLPP1 Association. <i>Blood</i> , <b>2010</b> , 116, 772-772	2.2	1
170	OSI-027, a Dual TORC1/TORC2 Inhibitor, Induces Bim- and Puma-Mediated Apoptosis In Lymphoid Malignancy. <i>Blood</i> , <b>2010</b> , 116, 970-970	2.2	1
169	Phase I Trial of the Oral Poly (ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888, V) Combined With Topotecan (T) and Carboplatin (C) for Adults with Relapsed and Refractory Acute Leukemias. <i>Blood</i> , <b>2010</b> , 116, 3276-3276	2.2	
168	Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. <i>Cancer Research</i> , <b>2009</b> , 69, 7635-43	10.1	42
167	Context-dependent Bcl-2/Bak interactions regulate lymphoid cell apoptosis. <i>Journal of Biological Chemistry</i> , <b>2009</b> , 284, 18311-22	5.4	42
166	Ataxia telangiectasia and rad3-related kinase contributes to cell cycle arrest and survival after cisplatin but not oxaliplatin. <i>Molecular Cancer Therapeutics</i> , <b>2009</b> , 8, 855-63	6.1	22
165	Mcl-1 degradation during hepatocyte lipoapoptosis. <i>Journal of Biological Chemistry</i> , <b>2009</b> , 284, 30039-48	5.4	34
164	On the role of topoisomerase I in mediating the cytotoxicity of 9-aminoacridine-based anticancer agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2009</b> , 19, 4459-62	2.9	13
163	The Nitric Acid Method for Protein Estimation in Biological Samples. <i>Springer Protocols</i> , <b>2009</b> , 35-45	0.3	
162	Reutilization of Western Blots After Chemiluminescent or Autoradiographic Detection. <i>Springer Protocols</i> , <b>2009</b> , 789-806	0.3	
161	Death receptor 5 internalization is required for lysosomal permeabilization by TRAIL in malignant liver cell lines. <i>Gastroenterology</i> , <b>2009</b> , 136, 2365-2376.e1-7	13.3	59
160	Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. <i>Blood</i> , <b>2009</b> , 113, 4841-52	2.2	51
159	Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. <i>Blood</i> , <b>2009</b> , 114, 2926-35	2.2	139
158	Deficiencies in Chfr and Mlh1 synergistically enhance tumor susceptibility in mice. <i>Journal of Clinical Investigation</i> , <b>2009</b> , 119, 2714-24	15.9	22
157	Combinations of the Histone Deacetylase Inhibitor Entinostat (SNDX-275, MS-275) and Imatinib Have Divergent Effects in Imatinib-Sensitive Vs. Imatinib-Resistant p210-BCR/ABL Expressing Cell Lines. <i>Blood</i> , <b>2009</b> , 114, 2742-2742	2.2	
156	Dynamics of granzyme B-induced apoptosis: mathematical modeling. <i>Mathematical Biosciences</i> , <b>2008</b> , 212, 54-68	3.9	4
155	Apoptosis-associated caspase activation assays. <i>Methods</i> , <b>2008</b> , 44, 262-72	4.6	63
154	Overcoming S-phase checkpoint-mediated resistance: sequence-dependent synergy of gemcitabine and 7-ethyl-10-hydroxycamptothecin (SN-38) in human carcinoma cell lines. <i>Molecular Pharmacology</i> , <b>2008</b> , 74, 724-35	4.3	8

153	BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. <i>Molecular Cancer Therapeutics</i> , <b>2008</b> , 7, 2339-47	6.1	37
152	Mitotic phosphorylation stimulates DNA relaxation activity of human topoisomerase I. <i>Journal of Biological Chemistry</i> , <b>2008</b> , 283, 16711-22	5.4	14
151	Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. <i>Cancer</i> , <b>2008</b> , 113, 508-14	6.4	193
150	Anticancer therapy: boosting the bang of Bim. <i>Journal of Clinical Investigation</i> , <b>2008</b> , 118, 3582-4	15.9	15
149	Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. <i>Journal of Biological Chemistry</i> , <b>2007</b> , 282, 18407-18417	5.4	89
148	Tumor necrosis factor-related apoptosis-inducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl-2 proteins. <i>Journal of Biological Chemistry</i> , <b>2007</b> , 282, 28960-28970	5.4	103
147	Genetic analysis of the short splice variant of the inhibitor of caspase-activated DNase (ICAD-S) in chicken DT40 cells. <i>Journal of Biological Chemistry</i> , <b>2007</b> , 282, 27374-27382	5.4	10
146	Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. <i>Journal of Biological Chemistry</i> , <b>2007</b> , 282, 29831-46	5.4	95
145	A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. <i>Blood</i> , <b>2007</b> , 109, 1387-94	2.2	163
144	The Intrinsic Pathway of Apoptosis <b>2007</b> , 3-30		3
143	Altered Apoptosis in AML <b>2007</b> , 133-161		1
142	Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. <i>Current Treatment Options in Oncology</i> , <b>2006</b> , 7, 285-94	5.4	67
141	Apoptosis in the treatment of cancer: a promise kept?. <i>Current Opinion in Cell Biology</i> , <b>2006</b> , 18, 668-76	9	59
140	Imatinib spells BAD news for Bcr/abl-positive leukemias. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 14651-2	11.5	8
139	Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. <i>Molecular Cancer Therapeutics</i> , <b>2006</b> , 5, 2378-87	6.1	96
138	Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. <i>Blood</i> , <b>2006</b> , 107, 2501-6	2.2	65
137	Synthesis of novel caspase inhibitors for characterization of the active caspase proteome in vitro and in vivo. <i>Journal of Medicinal Chemistry</i> , <b>2006</b> , 49, 7636-45	8.3	8
136	Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. <i>Journal of Clinical Investigation</i> , <b>2006</b> , 116, 1994-2004	15.9	105

135	Oral Tipifarnib (R115777) Has Single Agent Anti-Tumor Activity in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma (NHL): Results of a Phase II Trial in the University of Iowa/Mayo Clinic Lymphoma SPORE (CA97274).. <i>Blood</i> , <b>2006</b> , 108, 530-530	2.2	5
134	Genetic analysis of apoptotic execution. <i>Sub-Cellular Biochemistry</i> , <b>2006</b> , 40, 75-90	5.5	1
133	Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. <i>Gastroenterology</i> , <b>2005</b> , 128, 2054-65	13.3	182
132	Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine. <i>Blood</i> , <b>2005</b> , 105, 2099-106	2.2	38
131	Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. <i>Blood</i> , <b>2005</b> , 106, 318-27	2.2	110
130	Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer. <i>Oncogene</i> , <b>2005</b> , 24, 5089-100	9.2	51
129	The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. <i>Oncogene</i> , <b>2005</b> , 24, 6861-9	9.2	240
128	Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia. <i>American Journal of Hematology</i> , <b>2005</b> , 79, 119-27	7.1	3
127	Use of Camptothecins in the Treatment of Leukemia and Related Disorders <b>2005</b> , 421-450		1
126	Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 6641-9	12.9	24
125	The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 14349-55	5.4	87
124	Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 5347-56	2.2	455
123	Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 5935-41	12.9	61
122	Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 8403-12	12.9	78
121	Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl) (SCH66336). <i>Molecular Pharmacology</i> , <b>2005</b> , 68, 477-86	4.3	11
120	Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. <i>Molecular Pharmacology</i> , <b>2005</b> , 68, 1636-44	4.3	108
119	Approaches Used to Detect Apoptosis <b>2005</b> , 35-54		
118	Genomic mechanisms of p210BCR-ABL signaling: induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis. <i>Journal of Biological Chemistry</i> , <b>2004</b> , 279, 35604-15	5.4	45

117	Rad9 protects cells from topoisomerase poison-induced cell death. <i>Journal of Biological Chemistry</i> , <b>2004</b> , 279, 18641-7	5.4	36
116	Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. <i>Cancer Research</i> , <b>2004</b> , 64, 3517-24	10.1	197
115	Components of the cell death machine and drug sensitivity of the National Cancer Institute Cell Line Panel. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 6807-20	12.9	57
114	Caspase-7 gene disruption reveals an involvement of the enzyme during the early stages of apoptosis. <i>Journal of Biological Chemistry</i> , <b>2004</b> , 279, 1030-9	5.4	31
113	A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer. <i>Oncogene</i> , <b>2004</b> , 23, 1636-44	9.2	133
112	Apoptosis: an optimization approach. <i>Computers in Biology and Medicine</i> , <b>2004</b> , 34, 449-59	7	4
111	Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin. <i>Leukemia and Lymphoma</i> , <b>2004</b> , 45, 1545-9	1.9	43
110	Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. <i>Blood</i> , <b>2004</b> , 103, 3271-7	2.2	150
109	Hopes for kinase inhibitors active against AML take FLT. <i>Blood</i> , <b>2004</b> , 103, 8-8	2.2	
108	Anti-Tumor Activity of Single-Agent CCI-779 for Relapsed Mantle Cell Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group.. <i>Blood</i> , <b>2004</b> , 104, 129-129	2.2	3
107	Effects of Adaphostin, a Novel Tyrophostin Inhibitor, in Diverse Models of Imatinib Mesylate Resistance.. <i>Blood</i> , <b>2004</b> , 104, 2097-2097	2.2	1
106	S-peptide epitope tagging for protein purification, expression monitoring, and localization in mammalian cells. <i>BioTechniques</i> , <b>2004</b> , 37, 835-9	2.5	36
105	Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 23107-17	5.4	195
104	Heterogeneous role of caspase-8 in fenretinide-induced apoptosis in epithelial ovarian carcinoma cell lines. <i>Molecular Pharmacology</i> , <b>2003</b> , 64, 1434-43	4.3	22
103	Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group. <i>Cancer</i> , <b>2003</b> , 97, 2352-8	6.4	33
102	Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. <i>Oncogene</i> , <b>2003</b> , 22, 7414-30	9.2	228
101	Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 47326-39	5.4	49
100	Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 1760-6	2.2	158

99	Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells. <i>Blood</i> , <b>2003</b> , 102, 4512-9	2.2	60
98	A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 2520-6	12.9	34
97	G(1) and G(2) cell-cycle arrest following microtubule depolymerization in human breast cancer cells. <i>Journal of Clinical Investigation</i> , <b>2002</b> , 110, 91-9	15.9	145
96	A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer. <i>Investigational New Drugs</i> , <b>2002</b> , 20, 297-304	4.3	5
95	Caspase-6 gene disruption reveals a requirement for lamin A cleavage in apoptotic chromatin condensation. <i>EMBO Journal</i> , <b>2002</b> , 21, 1967-77	13	197
94	Lack of correlation between caspase activation and caspase activity assays in paclitaxel-treated MCF-7 breast cancer cells. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 804-15	5.4	55
93	Phorbol 12-myristate 13-acetate inhibits death receptor-mediated apoptosis in Jurkat cells by disrupting recruitment of Fas-associated polypeptide with death domain. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 3776-83	5.4	66
92	Reutilization of Western Blots After Chemiluminescent Detection or Autoradiography <b>2002</b> , 439-452		1
91	Calpain-mediated X-linked inhibitor of apoptosis degradation in neutrophil apoptosis and its impairment in chronic neutrophilic leukemia. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 33968-77	5.4	83
90	Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 44236-43	5.4	209
89	The Nitric Acid Method for Protein Estimation in Biological Samples <b>2002</b> , 31-40		
88	Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. <i>Blood</i> , <b>2002</b> , 99, 664-71	2.2	100
87	S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 1599-606	5.4	156
86	Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. <i>Gastroenterology</i> , <b>2002</b> , 122, 985-93	13.3	149
85	Neutropenic colitis after treatment of acute myelogenous leukemia with idarubicin and cytosine arabinoside. <i>Mayo Clinic Proceedings</i> , <b>2002</b> , 77, 760-2	6.4	26
84	Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. <i>Cancer Research</i> , <b>2002</b> , 62, 6500-5	10.1	61
83	Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. <i>Blood</i> , <b>2001</b> , 97, 3361-9	2.2	403
82	Enhanced ceramide generation and induction of apoptosis in human leukemia cells exposed to DT(388)-granulocyte-macrophage colony-stimulating factor (GM-CSF), a truncated diphtheria toxin fused to human GM-CSF. <i>Blood</i> , <b>2001</b> , 98, 1927-34	2.2	17

81	Current status of clinical trials of farnesyltransferase inhibitors. <i>Current Opinion in Oncology</i> , <b>2001</b> , 13, 470-6	4.2	85
80	Human INCENP colocalizes with the Aurora-B/AIRK2 kinase on chromosomes and is overexpressed in tumour cells. <i>Chromosoma</i> , <b>2001</b> , 110, 65-74	2.8	89
79	Reutilization of immunoblots after chemiluminescent detection. <i>Analytical Biochemistry</i> , <b>2001</b> , 296, 283-91	5.1	57
78	Is TRAIL hepatotoxic?. <i>Hepatology</i> , <b>2001</b> , 34, 3-6	11.2	69
77	Programmed cell death: alive and well in the new millennium. <i>Trends in Cell Biology</i> , <b>2001</b> , 11, 526-34	18.3	540
76	Analysis of caspase activation during apoptosis. <i>Current Protocols in Cell Biology</i> , <b>2001</b> , Chapter 18, Unit 18.2	2.3	6
75	A multistep model for paclitaxel-induced apoptosis in human breast cancer cell lines. <i>Experimental Cell Research</i> , <b>2001</b> , 270, 277-88	4.2	73
74	Caspases 3 and 9 send a pro-apoptotic signal from synapse to cell body in olfactory receptor neurons. <i>Journal of Neuroscience</i> , <b>2001</b> , 21, 7099-109	6.6	110
73	Apoptosis and the response to anticancer therapy. <i>Current Opinion in Oncology</i> , <b>2001</b> , 13, 453-62	4.2	67
72	Is TRAIL hepatotoxic?. <i>Hepatology</i> , <b>2001</b> , 34, 3-6	11.2	28
71	Apoptosis in cancer: cause and cure. <i>BioEssays</i> , <b>2000</b> , 22, 1007-17	4.1	149
70	Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia. <i>Blood</i> , <b>2000</b> , 96, 3922-3931	2.2	50
69	Effect of 6-aminonicotinamide and other protein synthesis inhibitors on formation of platinum-DNA adducts and cisplatin sensitivity. <i>Molecular Pharmacology</i> , <b>2000</b> , 57, 529-38	4.3	20
68	Retention of the human Rad9 checkpoint complex in extraction-resistant nuclear complexes after DNA damage. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 26343-8	5.4	88
67	Induction of apoptosis by cancer chemotherapy. <i>Experimental Cell Research</i> , <b>2000</b> , 256, 42-9	4.2	979
66	Detection of DNA cleavage in apoptotic cells. <i>Methods in Enzymology</i> , <b>2000</b> , 322, 3-15	1.7	38
65	Successful virtual screening of a chemical database for farnesyltransferase inhibitor leads. <i>Journal of Medicinal Chemistry</i> , <b>2000</b> , 43, 401-8	8.3	124
64	Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. <i>Journal of Clinical Investigation</i> , <b>2000</b> , 106, 1127-37	15.9	566

63	Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia. <i>Blood</i> , <b>2000</b> , 96, 3922-3931	2.2	5
62	Immunoblot analysis and band depletion assays. <i>Methods in Molecular Biology</i> , <b>1999</b> , 94, 253-68	1.4	14
61	Characterization of caspase processing and activation in HL-60 cell cytosol under cell-free conditions. Nucleotide requirement and inhibitor profile. <i>Journal of Biological Chemistry</i> , <b>1999</b> , 274, 22635-45	5.4	57
60	Caspase-mediated cleavage of DNA topoisomerase I at unconventional sites during apoptosis. <i>Journal of Biological Chemistry</i> , <b>1999</b> , 274, 4335-40	5.4	87
59	Comparison of paclitaxel-, 5-fluoro-2-deoxyuridine-, and epidermal growth factor (EGF)-induced apoptosis. Evidence for EGF-induced anoikis. <i>Journal of Biological Chemistry</i> , <b>1999</b> , 274, 15927-36	5.4	68
58	Mammalian caspases: structure, activation, substrates, and functions during apoptosis. <i>Annual Review of Biochemistry</i> , <b>1999</b> , 68, 383-424	29.1	2313
57	A one-step method for protein estimation in biological samples: nitration of tyrosine in nitric acid. <i>Analytical Biochemistry</i> , <b>1999</b> , 267, 217-21	3.1	26
56	Hypercalcemia complicating leukemic transformation of agnogenic myeloid metaplasia-myelofibrosis. <i>Mayo Clinic Proceedings</i> , <b>1999</b> , 74, 1233-7	6.4	11
55	Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent. <i>Biochemical Pharmacology</i> , <b>1999</b> , 58, 1057-66	6	20
54	Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. <i>Journal of Clinical Investigation</i> , <b>1999</b> , 103, 137-45	15.9	425
53	Apparent cleavage of poly(ADP-ribose) polymerase in non-apoptotic mouse LTA cells: an artifact of cross-reactive secondary antibody. <i>Molecular and Cellular Biochemistry</i> , <b>1998</b> , 178, 245-9	4.2	6
52	Cell death induced by topoisomerase-targeted drugs: more questions than answers. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , <b>1998</b> , 1400, 195-211		215
51	Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1998</b> , 42, 391-9	3.5	58
50	Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells. <i>Gastroenterology</i> , <b>1998</b> , 114, 930-9	13.3	73
49	Topoisomerase II and the response to antileukemic therapy. <i>Leukemia and Lymphoma</i> , <b>1998</b> , 29, 217-37	1.9	19
48	Transition from caspase-dependent to caspase-independent mechanisms at the onset of apoptotic execution. <i>Journal of Cell Biology</i> , <b>1998</b> , 143, 225-39	7.3	116
47	Phosphorylated Forms of Activated Caspases Are Present in Cytosol From HL-60 Cells During Etoposide-Induced Apoptosis. <i>Blood</i> , <b>1998</b> , 92, 3042-3049	2.2	48
46	Elevated Expression of the Apoptotic Regulator Mcl-1 at the Time of Leukemic Relapse. <i>Blood</i> , <b>1998</b> , 91, 991-1000	2.2	235



45	Elevated Expression of the Apoptotic Regulator Mcl-1 at the Time of Leukemic Relapse. <i>Blood</i> , <b>1998</b> , 91, 991-1000	2.2	218
44	Phosphorylated Forms of Activated Caspases Are Present in Cytosol From HL-60 Cells During Etoposide-Induced Apoptosis. <i>Blood</i> , <b>1998</b> , 92, 3042-3049	2.2	12
43	The Role of Proteases in Neuronal Apoptosis. <i>Frontiers in Neuroscience</i> , <b>1998</b> ,		1
42	Erasure of western blots after autoradiographic or chemiluminescent detection. <i>Methods in Molecular Biology</i> , <b>1998</b> , 80, 223-35	1.4	11
41	Activation of multiple interleukin-1beta converting enzyme homologues in cytosol and nuclei of HL-60 cells during etoposide-induced apoptosis. <i>Journal of Biological Chemistry</i> , <b>1997</b> , 272, 7421-30	5.4	176
40	Chemotherapy-induced apoptosis. <i>Advances in Pharmacology</i> , <b>1997</b> , 41, 461-99	5.7	105
39	Methods utilized in the study of apoptosis. <i>Advances in Pharmacology</i> , <b>1997</b> , 41, 57-87	5.7	36
38	Comparison of Caspase Activation and Subcellular Localization in HL-60 and K562 Cells Undergoing Etoposide-Induced Apoptosis. <i>Blood</i> , <b>1997</b> , 90, 4283-4296	2.2	116
37	Altered Formation of Topotecan-Stabilized Topoisomerase I-DNA Adducts in Human Leukemia Cells. <i>Blood</i> , <b>1997</b> , 89, 2098-2104	2.2	49
36	Comparison of Apoptosis in Wild-Type and Fas-Resistant Cells: Chemotherapy-Induced Apoptosis Is Not Dependent on Fas/Fas Ligand Interactions. <i>Blood</i> , <b>1997</b> , 90, 935-943	2.2	242
35	Caspases and caspase inhibitors. <i>Trends in Biochemical Sciences</i> , <b>1997</b> , 22, 388-93	10.3	469
34	Resistance to topoisomerase II poisons: is the answer in the promoter?. <i>Leukemia Research</i> , <b>1997</b> , 21, 1033-6	2.7	1
33	Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein. <i>International Journal of Cancer</i> , <b>1997</b> , 71, 817-24	7.5	46
32	Comparison of Caspase Activation and Subcellular Localization in HL-60 and K562 Cells Undergoing Etoposide-Induced Apoptosis. <i>Blood</i> , <b>1997</b> , 90, 4283-4296	2.2	4
31	Comparison of Apoptosis in Wild-Type and Fas-Resistant Cells: Chemotherapy-Induced Apoptosis Is Not Dependent on Fas/Fas Ligand Interactions. <i>Blood</i> , <b>1997</b> , 90, 935-943	2.2	18
30	Addition of etoposide to initial therapy of adult acute lymphoblastic leukemia: a combined clinical and laboratory study. <i>Leukemia and Lymphoma</i> , <b>1996</b> , 23, 71-83	1.9	13
29	Evaluation of 2,6-diamino-N-([1-(1-oxotridecyl)-2-piperidiny]methyl)- hexanamide (NPC 15437), a protein kinase C inhibitor, as a modulator of P-glycoprotein-mediated resistance in vitro. <i>Investigational New Drugs</i> , <b>1996</b> , 13, 285-94	4.3	7
28	Factors affecting topotecan sensitivity in human leukemia samples. <i>Annals of the New York Academy of Sciences</i> , <b>1996</b> , 803, 128-42	6.5	9

27	Proteolytic cleavage during chemotherapy-induced apoptosis. <i>Trends in Molecular Medicine</i> , <b>1996</b> , 2, 298-303		25
26	Alteration of the nucleolar localization of poly(ADP-ribose) polymerase upon treatment with transcription inhibitors. <i>Experimental Cell Research</i> , <b>1996</b> , 227, 146-53	4.2	58
25	The role of proteases during apoptosis. <i>FASEB Journal</i> , <b>1996</b> , 10, 587-97	0.9	491
24	Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. <i>Journal of the National Cancer Institute</i> , <b>1996</b> , 88, 734-41	9.7	143
23	Effect of v-rasH on sensitivity of NCI-H82 human small cell lung cancer cells to cisplatin, etoposide, and camptothecin. <i>Biochemical Pharmacology</i> , <b>1995</b> , 50, 1987-93	6	6
22	Detection of poly(ADP-ribose) polymerase and its apoptosis-specific fragment by a nonisotopic activity-western blot technique. <i>Analytical Biochemistry</i> , <b>1995</b> , 232, 251-4	3.1	43
21	Camptothecin analogues: studies from the Johns Hopkins Oncology Center. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1994</b> , 34 Suppl, S53-7	3.5	27
20	Topoisomerases in human leukemia. <i>Advances in Pharmacology</i> , <b>1994</b> , 29B, 33-50	5.7	3
19	The current status of camptothecin analogues as antitumor agents. <i>Journal of the National Cancer Institute</i> , <b>1993</b> , 85, 271-91	9.7	512
18	Erasure of western blots after autoradiography or chemiluminescent detection. <i>Applied Biochemistry and Biotechnology</i> , <b>1993</b> , 38, 243-55	3.2	1
17	Erasable Western blots. <i>Methods in Molecular Biology</i> , <b>1992</b> , 80, 235-46	1.4	
16	Proteolytic Cleavage of Poly(ADP-Ribose) Polymerase in Human Leukemia Cells Treated with Etoposide and other Cytotoxic Agents <b>1992</b> , 260-268		
15	Expression of poly (ADP-ribose) polymerase in differentiating HL-60 cells <b>1992</b> , 92-94		
14	Association of topoisomerase II with the hepatoma cell nuclear matrix: the role of intermolecular disulfide bond formation. <i>Experimental Cell Research</i> , <b>1991</b> , 192, 511-23	4.2	52
13	Association of poly(ADP-ribose) polymerase with the nuclear matrix: the role of intermolecular disulfide bond formation, RNA retention, and cell type. <i>Experimental Cell Research</i> , <b>1991</b> , 192, 524-35	4.2	54
12	Severe graft-versus-host disease in a liver-transplant recipient. <i>New England Journal of Medicine</i> , <b>1988</b> , 318, 689-91	59.2	154
11	The erasable Western blot. <i>Analytical Biochemistry</i> , <b>1987</b> , 161, 89-95	3.1	149
10	Analysis of the internal nuclear matrix. Oligomers of a 38 kD nucleolar polypeptide stabilized by disulfide bonds. <i>Experimental Cell Research</i> , <b>1986</b> , 164, 139-53	4.2	52

9	A subset of non-histone nuclear proteins reversibly stabilized by the sulfhydryl cross-linking reagent tetrathionate. Polypeptides of the internal nuclear matrix. <i>Experimental Cell Research</i> , <b>1984</b> , 155, 477-95	4.2	133
8	Binding of dexamethasone to rat liver nuclei in vivo and in vitro: evidence for two distinct binding sites. <i>The Journal of Steroid Biochemistry</i> , <b>1984</b> , 20, 699-708		22
7	An alternative approach to the quantitation of glucocorticoid-receptor complexes in the nuclei of lymphoid cells. <i>Endocrinology</i> , <b>1982</b> , 110, 708-16	4.8	15
6	Considerations in the isolation of rat liver nuclear matrix, nuclear envelope, and pore complex lamina. <i>Experimental Cell Research</i> , <b>1981</b> , 132, 105-23	4.2	232
5	Increased phosphorylation rate of intermediate filaments during mitotic arrest. <i>Experimental Cell Research</i> , <b>1981</b> , 133, 445-8	4.2	20
4	The relationship of the nuclear matrix to cellular structure and function. <i>Advances in Enzyme Regulation</i> , <b>1978</b> , 17, 213-48		92
3	Apoptotic Pathways in Cancer Progression and Treatment 143-170		1
2	Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma		1
1	Characterization of a RAD51C-Silenced High Grade Serous Ovarian Cancer Model During PARP Inhibitor Resistance Development		1